Skip to main content
Article thumbnail
Location of Repository

Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance

By D. James Nokes, Mwanajuma Ngama, Anne Bett, John Abwao, Patrick Munywoki, M. (Mike) English, J. Anthony G. Scott, Patricia Cane and Graham Medley


Background.Although necessary for developing a rationale for vaccination, the burden of severe respiratory syncytial virus (RSV) disease in children in resource‐poor settings remains poorly defined.\ud \ud Methods.We conducted prospective surveillance of severe and very severe pneumonia in children aged <5 years admitted from 2002 through 2007 to Kilifi district hospital in coastal Kenya. Nasal specimens were screened for RSV antigen by immunofluorescence. Incidence rates were estimated for the well‐defined population.\ud \ud Results.Of 25,149 hospital admissions, 7359 patients (29%) had severe or very severe pneumonia, of whom 6026 (82%) were enrolled. RSV prevalence was 15% (20% among infants) and 27% during epidemics (32% among infants). The proportion of case patients aged 3 months was 65%, and the proportion aged 6 months was 43%. Average annual hospitalization rates were 293 hospitalizations per 100,000 children aged <5 years (95% confidence interval, 271–371 hospitalizations per 100,000 children aged <5 years) and 1107 hospitalizations per 100,000 infants (95% confidence interval, 1012–1211 hospitalizations per 100,000 infants). Hospital admission rates were double in the region close to the hospital. Few patients with RSV infection had life‐threatening clinical features or concurrent serious illnesses, and the associated mortality was 2.2%.\ud \ud Conclusions.In this low‐income setting, rates of hospital admission with RSV‐associated pneumonia are substantial; they are comparable to estimates from the United States but considerably underestimate the burden in the full community. An effective vaccine for children aged >2 months (outside the age group of poor responders) could prevent a large portion of RSV disease. Severity data suggest that the justification for RSV vaccination will be based on the prevention of morbidity, not mortality

Topics: RA0421, RJ
Publisher: University of Chicago Press
OAI identifier:

Suggested articles


  1. (2002). An epidemiological study of RSV infection in the Gambia. Bull World Health Organ
  2. (2008). Comparison of direct immunofluorescence, conventional cell culture and polymerase chain reaction techniques for detecting respiratory syncytial virus in nasopharyngeal aspirates from infants. Rev Inst Med Trop Sao Paulo doi
  3. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. doi
  4. Comparison of three methods of collecting nasal specimens for respiratory virus analysis. doi
  5. (2002). Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. Pediatr Infect Dis J doi
  6. Evaluation of a live, cold-passaged, temperature-sensitive, respiratorysyncytialvirusvaccinecandidate in infancy.
  7. (1999). Evaluation of vaccines for the prevention of pneumonia in children in developing countries. Epidemiol Rev doi
  8. (2008). Factors associated with increased risk of progression to respiratory syncytial virus–associated pneumonia in young Kenyan children. Trop Med Int Health doi
  9. (2009). for Disease Control and Prevention/World Health Orgnization. PATH Rotavirus Vaccine Program. Available at: http://www
  10. (2008). IDB summary demographic data for Kenya,
  11. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. doi
  12. (2007). Immunopathology of RSV infection: prospectsfordevelopingvaccineswithout this complication. Rev Med Virol doi
  13. Incidence and clinical characteristics of group A rotavirus infections among children admitted to hospital in Kilifi, doi
  14. (2002). Ministry of Finance and Planning. Analytical report on population projections. Volume VII.
  15. Respiratory syncytial virus disease burden in the developing world. doi
  16. (2003). Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J doi
  17. Respiratory syncytial virus epidemiology in a birth cohort from Kilifi District, Kenya: infection during the first year of life. doi
  18. Respiratory syncytial virus infection in tropical and developing countries. TropMed IntHealth1998;3: doi
  19. Respiratory syncytial virus infection: denominator-based studies in
  20. Respiratorysyncytialvirusinfection and disease in infants and young children observed from birth doi
  21. (1993). Statistical models inepidemiology.NewYork:Oxford
  22. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. doi
  23. The burden of respiratory syncytial virus infection in young children. doi
  24. (1998). The clinical spectrum of respiratory syncytial virus disease in The Gambia. Pediatr Infect Dis J doi
  25. The decline in paediatric malaria admissions on the coast of Kenya. doi
  26. Vaccines against human respiratory syncytial virus. doi
  27. (2008). What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.